Substituted imidazolylmethyl pyridine and pyrazine derivatives that bind
to GABAA receptors are provided. Such compounds may be used to modulate
ligand binding to GABAA receptors in vivo or in vitro, and are particularly
useful in the treatment of a variety of central nervous system (CNS) disorders
in humans, domesticated companion animals and livestock animals. Compounds provided
herein may be administered alone or in combination with one or more other CNS agents
to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions
and methods for treating such disorders are provided, as are methods for using
such ligands for detecting GABAA receptors (e.g., receptor localization studies).